Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Shares Outstanding (Weighted Average) (2018 - 2025)

Black Diamond Therapeutics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $56.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.34% year-over-year to $56.9 million; the TTM value through Dec 2025 reached $56.9 million, up 3.34%, while the annual FY2025 figure was $56.9 million, 3.34% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $56.9 million in Q4 2025 per BDTX's latest filing, roughly flat from $56.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $56.9 million in Q3 2025 to a low of $36.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 3 years is $50.2 million, with a median of $55.0 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 52.42% in 2021, then grew 0.75% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $36.2 million in 2021, then surged by 51.93% to $55.0 million in 2024, then grew by 3.34% to $56.9 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Shares Outstanding (Weighted Average) are $56.9 million (Q4 2025), $56.9 million (Q3 2025), and $56.7 million (Q2 2025).